Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter J. Adamson is active.

Publication


Featured researches published by Peter J. Adamson.


Cancer Epidemiology, Biomarkers & Prevention | 2005

Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes

Tracy Lightfoot; Christine F. Skibola; Eleanor V. Willett; Danica R. Skibola; James M. Allan; Fabio Coppede; Peter J. Adamson; Gareth J. Morgan; Eve Roman; Martyn T. Smith

Genetic instability, including chromosomal imbalance, is important in the pathogenesis of lymphoproliferative disorders such as non–Hodgkin lymphoma (NHL). DNA synthesis and methylation, which are closely linked to folate metabolism and transport, may be affected by polymorphisms in genes involved in these pathways. Folate metabolism polymorphisms have been linked to acute lymphoblastic leukemia and colorectal cancer. To evaluate whether genetic variation in folate metabolism and transport may have a role in determining the risk of developing NHL, we analyzed several polymorphisms using DNA obtained as part of a large U.K. population-based case-control study of lymphoma. Polymorphisms studied include methylenetetrahydrofolate reductase (MTHFR) 677 C>T and 1298 A>C, methionine synthase (MTR) 2756 A>G, serine hydroxymethyltransferase (SHMT1) 1420 C>T, thymidylate synthase (TYMS) 1494del6 and 28–bp repeat, and reduced folate carrier (RFC) 80 G>A. Increased risks for NHL [odds ratio (OR), 1.48; 95% confidence intervals (CI), 1.12-1.97], and marginal zone lymphoma (OR, 3.38; 95% CI, 1.30-8.82) were associated with the TYMS 2R/3R variant. Marginal increased risks were also observed for diffuse large B cell lymphoma with the TYMS homozygous 6 bp deletion (OR, 1.61; 95% CI, 0.99-2.60) and for follicular lymphoma with RFC 80AA (OR, 1.44; 95% CI, 0.94-2.22) and TYMS 28–bp repeat 2R/3R (OR, 1.45; 95% CI, 0.96-2.2). We observed no association between NHL and haplotypes for MTHFR or TYMS. These findings are somewhat inconsistent with those of others, but may reflect differences in circulating folate levels between study populations. Thus, further investigations are warranted in larger series with dietary information to determine the roles that genetics and folic acid status play in the etiology of lymphoma. (Cancer Epidemiol Biomarkers Prev 2005;14(12):2999–3003)


British Journal of Cancer | 2005

Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms

Eleanor V. Willett; Christine F. Skibola; Peter J. Adamson; Danica R. Skibola; Gareth J. Morgan; Martyn T. Smith; Eve Roman

A population-based case–control study of lymphomas in England collected height and weight details from 699 non-Hodgkins lymphoma (NHL) cases and 914 controls. Obesity, defined as a body mass index (BMI) over 30 kg m−2 at five years before diagnosis,, was associated with an increased risk of NHL (OR=1.5, 95% CI 1.1–2.1). The excess was most pronounced for diffuse large B-cell lymphoma (OR=1.9, 95% CI 1.3–2.8). Genetic variants in the leptin (LEP 19G>A, LEP −2548G>A) and leptin receptor genes (LEPR 223Q>R), previously shown to modulate NHL risk, as well as a polymorphism in the energy regulatory gene adiponectin (APM1 276G>T), were investigated. Findings varied with leptin genotype, the risks being decreased with LEP 19AA (OR=0.7, 95% CI 0.5–1.0) and increased with LEP −2548GA (OR=1.3, 95% CI 1.0–1.7) and −2548AA (OR=1.4, 95% CI 1.0–1.9), particularly for follicular lymphoma. These genetic findings, which were independent of BMI, were stronger for men than women.


British Journal of Haematology | 2005

Haplotypes in the tumour necrosis factor region and myeloma

Gareth J. Morgan; Peter J. Adamson; Fiona Mensah; Charlotte F. Spink; Graham R. Law; Leigh J. Keen; Eve Roman; Faith E. Davies; Sara Rollinson; J. A. Child; Jeffrey L. Bidwell

This study described the haplotypic structure across a region of chromosome 6 including the tumour necrosis factor (TNF) gene, and investigated its influence on the aetiology of myeloma. A total of 181 myeloma cases from the Medical Research Council Myeloma VII trial and 233 controls from the Leukaemia Research Fund Case Control Study of Adult Acute Leukaemia were included in the analysis. Genotyping by induced heteroduplex generator analysis was carried out for single nucleotide polymorphisms (SNP) located at positions −1031, −863, −857, −308 and −238 of the 5′ promoter region of TNF‐α gene, and 252 in the LT‐α gene; and five microsatellites, TNFa, b, c, d and e. Haplotypes were inferred statistically using the phase algorithm. A limited diversity of haplotypes was observed, with the majority of variation described by 12 frequent haplotypes. Detailed characterization of the haplotype did not provide greater determination of disease risk beyond that described by the TNF‐α−308 SNP. Some evidence was provided for a decreased risk of myeloma associated with the TNF‐α−308 variant allele A, odds ratio, 0·57; 95% confidence interval, 0·38–0·86. The results of this study did not support our starting hypothesis; that high producer haplotypes at the TNF locus are associated with an increased risk of developing myeloma.


Cancer Epidemiology | 2009

Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non-Hodgkin lymphoma

Lisa Worrillow; Eve Roman; Peter J. Adamson; Eleanor Kane; James M. Allan; Tracy Lightfoot

Non-Hodgkin lymphoma (NHL) represents a complex group of B- and T-cell malignancies characterised by chromosomal translocations. Since defects in DNA repair result in an increased frequency of chromosomal aberrations it has been hypothesised that genetic variation in DNA repair may be associated with risk of NHL. To investigate the relationship between DNA repair and NHL we analysed polymorphisms in XPD (R156R, D312N, K751Q) using DNA collected in a UK population-based case-control study of lymphoma. We observed no association between genetic variation in XPD and risk of NHL. However, the XPD 751 Gln allele was associated with a two-fold decreased risk of diffuse large B-cell lymphoma (OR 0.56, 95% CI 0.34-0.92, p=0.02), the major subtype of NHL. Overall, our study identifies that XPD polymorphisms may be important in the aetiology of NHL although analysis of additional polymorphisms and extended haplotype studies are required to clarify their role.


British Journal of Haematology | 2005

Polymorphisms in cytochrome P450 17A1 and risk of non-Hodgkin lymphoma

Christine F. Skibola; Tracy Lightfoot; Luz Agana; Alex Smith; Sara Rollinson; Andrew Kao; Peter J. Adamson; Gareth J. Morgan; Martyn T. Smith; Eve Roman

Broad cross‐talk exists between the endocrine and immune systems. Estrogen receptor expression in lymphocytes suggests that hormonal modulation may influence lymphoma risk. Analysis of genetic polymorphisms that affect oestrogen production, such as cytochrome P450 17A1 (CYP17A1) −34T>C, may provide insight into oestrogens role in lymphomagenesis. CYP17A1−34T>C and CYP17A1 IVS2 105A>C polymorphisms were analyzed in a non‐Hodgkin lymphoma (NHL) population‐based case–control study. The CYP17A1−34CC genotype was positively associated with NHL [odds ratio (OR) = 1·44, 95% confidence interval (CI) 1·02–2·03], particularly diffuse large B‐cell lymphoma (OR = 1·76, CI 1·14–2·71). Associations of CYP17A1 polymorphisms with increased risk of NHL suggest a role for oestrogen in lymphomagenesis.


Haematologica | 2008

Genetic variation in genes expressed in the germinal center and risk of B cell lymphoma among Caucasians

Kathryn Scott; Peter J. Adamson; Eleanor V. Willett; Lisa Worrillow; James M. Allan

The germinal center reaction is integral to B-cell maturation, where class switch recombination (CSR) and somatic hypermutation (SHM) are targeted to the immunoglobulin (Ig) locus to facilitate antibody diversity.[1][1] Selection against B cells with auto-reactive or low affinity antigen receptors


Blood | 2003

Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma

Ranjit Dasgupta; Peter J. Adamson; Faith E. Davies; Sara Rollinson; Philippa L. Roddam; Andrew J. Ashcroft; Ann M. Dring; James A. L. Fenton; J. A. Child; James M. Allan; Gareth J. Morgan


Haematologica | 2006

Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma

Tracy Lightfoot; Christine F. Skibola; Alex Smith; Matthew S. Forrest; Peter J. Adamson; Gareth J. Morgan; Paige M. Bracci; Eve Roman; Martyn T. Smith; Elizabeth A. Holly


European Journal of Cancer | 2007

Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe

Peter J. Adamson; Freddie Bray; Adele Seniori Costantini; Meng Hua Tao; Elisabete Weiderpass; Eve Roman


Leukemia Research | 2007

RAD51 homologous recombination repair gene haplotypes and risk of acute myeloid leukaemia

Sara Rollinson; Alexandra Smith; James M. Allan; Peter J. Adamson; Kathryn Scott; Christine F. Skibola; Martyn T. Smith; Gareth J. Morgan

Collaboration


Dive into the Peter J. Adamson's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gareth J. Morgan

Leeds Teaching Hospitals NHS Trust

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christine F. Skibola

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge